Literature DB >> 12525664

In a subset of subjects on highly active antiretroviral therapy, human immunodeficiency virus type 1 RNA in plasma decays from 50 to <5 copies per milliliter, with a half-life of 6 months.

Michele Di Mascio1, Geethanjali Dornadula, Hui Zhang, Julie Sullivan, Yan Xu, Joseph Kulkosky, Roger J Pomerantz, Alan S Perelson.   

Abstract

Three of five virally suppressed human immunodeficiency virus type I (HIV-1)-infected patients treated with highly active antiretroviral therapy and followed intensively with a supersensitive reverse transcriptase PCR assay with a lower limit of quantitation of 5 copies/ml showed statistically significant viral load decays below 50 copies/ml, with half-lives of 5 to 8 months and a mean of 6 months. This range of half-lives is consistent with the estimated half-life of the latent HIV-1 reservoir in the peripheral blood. Those patients without decay of viral load in plasma may have significant cryptic HIV-1 residual replication.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12525664      PMCID: PMC140859          DOI: 10.1128/jvi.77.3.2271-2275.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection.

Authors:  W Cavert; D W Notermans; K Staskus; S W Wietgrefe; M Zupancic; K Gebhard; K Henry; Z Q Zhang; R Mills; H McDade; C M Schuwirth; J Goudsmit; S A Danner; A T Haase
Journal:  Science       Date:  1997-05-09       Impact factor: 47.728

2.  Endogenous reverse transcription of human immunodeficiency virus type 1 in physiological microenviroments: an important stage for viral infection of nondividing cells.

Authors:  H Zhang; G Dornadula; R J Pomerantz
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

3.  HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.

Authors:  A S Perelson; A U Neumann; M Markowitz; J M Leonard; D D Ho
Journal:  Science       Date:  1996-03-15       Impact factor: 47.728

4.  Reverse transcription takes place within extracellular HIV-1 virions: potential biological significance.

Authors:  H Zhang; Y Zhang; T P Spicer; L Z Abbott; M Abbott; B J Poiesz
Journal:  AIDS Res Hum Retroviruses       Date:  1993-12       Impact factor: 2.205

5.  HIV-1 infection and low steady state viral loads.

Authors:  Duncan S Callaway; Alan S Perelson
Journal:  Bull Math Biol       Date:  2002-01       Impact factor: 1.758

6.  Kinetic analysis of intravirion reverse transcription in the blood plasma of human immunodeficiency virus type 1-infected individuals: direct assessment of resistance to reverse transcriptase inhibitors in vivo.

Authors:  H Zhang; G Dornadula; Y Wu; D Havlir; D D Richman; R J Pomerantz
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

7.  Lifespan of human lymphocyte subsets defined by CD45 isoforms.

Authors:  C A Michie; A McLean; C Alcock; P C Beverley
Journal:  Nature       Date:  1992-11-19       Impact factor: 49.962

8.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

9.  Viral dynamics in human immunodeficiency virus type 1 infection.

Authors:  X Wei; S K Ghosh; M E Taylor; V A Johnson; E A Emini; P Deutsch; J D Lifson; S Bonhoeffer; M A Nowak; B H Hahn
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

10.  Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA.

Authors:  R D Hockett; J M Kilby; C A Derdeyn; M S Saag; M Sillers; K Squires; S Chiz; M A Nowak; G M Shaw; R P Bucy
Journal:  J Exp Med       Date:  1999-05-17       Impact factor: 14.307

View more
  25 in total

Review 1.  Immune-based therapies: an adjunct to antiretroviral treatment.

Authors:  Jeffrey M Jacobson
Journal:  Curr HIV/AIDS Rep       Date:  2005-06       Impact factor: 5.071

2.  Contribution of follicular dendritic cells to persistent HIV viremia.

Authors:  Jingshan Zhang; Alan S Perelson
Journal:  J Virol       Date:  2013-05-08       Impact factor: 5.103

3.  Depletion of latent HIV-1 infection in vivo: a proof-of-concept study.

Authors:  Ginger Lehrman; Ian B Hogue; Sarah Palmer; Cheryl Jennings; Celsa A Spina; Ann Wiegand; Alan L Landay; Robert W Coombs; Douglas D Richman; John W Mellors; John M Coffin; Ronald J Bosch; David M Margolis
Journal:  Lancet       Date:  2005 Aug 13-19       Impact factor: 79.321

4.  Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens.

Authors:  Silvia Baroncelli; Maria Franca Pirillo; Clementina Maria Galluzzo; Anna Degli Antoni; Nicoletta Ladisa; Daniela Francisci; Gabriella d'Ettorre; Daniela Segala; Angela Vivarelli; Federica Sozio; Oscar Cirioni; Liliana Elena Weimer; Vincenzo Fragola; Giustino Parruti; Marco Floridia
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

Review 5.  Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage.

Authors:  Valentin Le Douce; Georges Herbein; Olivier Rohr; Christian Schwartz
Journal:  Retrovirology       Date:  2010-04-09       Impact factor: 4.602

6.  Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy.

Authors:  Laura E Jones; Alan S Perelson
Journal:  J Acquir Immune Defic Syndr       Date:  2007-08-15       Impact factor: 3.731

7.  Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infection.

Authors:  Leor S Weinberger; David V Schaffer; Adam P Arkin
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

8.  Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.

Authors:  Sarah Palmer; Frank Maldarelli; Ann Wiegand; Barry Bernstein; George J Hanna; Scott C Brun; Dale J Kempf; John W Mellors; John M Coffin; Martin S King
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-10       Impact factor: 11.205

9.  Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.

Authors:  Nancy M Archin; Joseph J Eron; Sarah Palmer; Anne Hartmann-Duff; Jeffery A Martinson; Ann Wiegand; Nicholas Bandarenko; John L Schmitz; Ronald J Bosch; Alan L Landay; John M Coffin; David M Margolis
Journal:  AIDS       Date:  2008-06-19       Impact factor: 4.177

10.  Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy.

Authors:  Libin Rong; Alan S Perelson
Journal:  PLoS Comput Biol       Date:  2009-10-16       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.